Emilio Jesús Alegre Del Rey
YOU?
Author Swipe
View article: Economic Evaluation of Treatment With Trastuzumab Deruxtecan for HER2-Low Advanced or Metastatic Breast Cancer in Previously Treated Patients
Economic Evaluation of Treatment With Trastuzumab Deruxtecan for HER2-Low Advanced or Metastatic Breast Cancer in Previously Treated Patients Open
View article: [Translated article] The relevance of therapeutic positioning in the post-approval evaluation of new drugs
[Translated article] The relevance of therapeutic positioning in the post-approval evaluation of new drugs Open
The objective of regulatory authorities is to ensure a favourable risk-benefit balance for medicines in their licenced indication, without seeking to establish their place in the therapeutic armamentarium beyond that. The licenced indicati…
View article: Cost-Effectiveness of Sacituzumab Govitecan Treatment for Metastatic Triple Negative Breast Cancer
Cost-Effectiveness of Sacituzumab Govitecan Treatment for Metastatic Triple Negative Breast Cancer Open
View article: Guideline for the economic evaluation of medicines: a proposal by the Spanish National Health System's Advisory Committee for Pharmaceutical Financing
Guideline for the economic evaluation of medicines: a proposal by the Spanish National Health System's Advisory Committee for Pharmaceutical Financing Open
In 2023, the General Directorate of Pharmacy of the Ministry of Health commissioned the Advisory Committee on the Financing of Pharmaceuticals for the National Health System (CAPF, Comité Asesor para la Financiación de la Prestación Farmac…
View article: Reform of economic evaluation of medicines in Spain: proposals from the Advisory Committee for Pharmaceutical Financing
Reform of economic evaluation of medicines in Spain: proposals from the Advisory Committee for Pharmaceutical Financing Open
This paper describes the reforms recommended by the Advisory Committee on the Financing of Pharmaceuticals (CAPF) for the National Health System (NHS) of Spain from 2019 to 2024 for the drug pricing and reimbursement process, to integrate …
View article: La importancia del posicionamiento terapéutico en la evaluación posautorización de nuevos medicamentos
La importancia del posicionamiento terapéutico en la evaluación posautorización de nuevos medicamentos Open
The objective of regulatory authorities is to ensure a favorable risk-benefit balance for medicines in their licensed indication, without seeking to establish their place in the therapeutic armamentarium beyond that. The licensed indicatio…
View article: 6ER-032 Adjusted indirect comparison of cemiplimab in combination with chemotherapy vs immunotherapy alone in the first-line treatment of metastatic non-small-cell lung cancer in patients with pd-l1≥50%
6ER-032 Adjusted indirect comparison of cemiplimab in combination with chemotherapy vs immunotherapy alone in the first-line treatment of metastatic non-small-cell lung cancer in patients with pd-l1≥50% Open
Background and Importance Cemiplimab with chemotherapy is licensed for the treatment of first line adult patients with locally advanced NSCLC who are not candidates for chemoradiation, or metastatic, expressing PD-L1≥1%. Cemiplimab alone h…
View article: 4CPS-106 AUC-survival reanalysis of TROPiCS-02 trial with sacituzumab govitecanfor metastatic luminal breast cancer
4CPS-106 AUC-survival reanalysis of TROPiCS-02 trial with sacituzumab govitecanfor metastatic luminal breast cancer Open
Background and Importance Sacituzumab govitecan (SG) was recently approved by European Medicines Agency for heavily treated metastatic breast cancer (mBC) patients positive hormone receptor (HR+) and human epidermal growth factor receptor-…
View article: 4CPS-226 Pharmaceutical intervention on the adequacy of the indication of semaglutide in diabetes mellitus 2
4CPS-226 Pharmaceutical intervention on the adequacy of the indication of semaglutide in diabetes mellitus 2 Open
Background and Importance Semaglutide is a GLP-1 analogue approved for the treatment of adults with poorly controlled type 2 diabetes mellitus (DMII). It has been shown to reduce blood glucose levels and the risk of health complications. I…
View article: 6ER-033 Adjusted indirect comparison of cemiplimab in combination with chemotherapy vs immunotherapy alone in the first-line treatment of metastatic non-small-cell lung cancer in patients with pd-l1≥1%
6ER-033 Adjusted indirect comparison of cemiplimab in combination with chemotherapy vs immunotherapy alone in the first-line treatment of metastatic non-small-cell lung cancer in patients with pd-l1≥1% Open
Background and Importance Cemiplimab, pembrolizumab, atezolizumab ± bevacizumab, nivolumab + ipilimumab and durvalumab + tremelimumab in combination with chemotherapy, and nivolumab + ipilimumab, are licensed for the treatment of 1L adult …
View article: 4CPS-175 Effectiveness of immunotherapy as a function of age: meta-analysis of the approved combinations in first-line metastatic non-small-cell lung cancer in patients without mutations
4CPS-175 Effectiveness of immunotherapy as a function of age: meta-analysis of the approved combinations in first-line metastatic non-small-cell lung cancer in patients without mutations Open
Background and Importance It could be hypothesised that patients older than 65 years old may experience decreased immune function due to the natural aging process, which could lead to a more limited response to immunotherapy compared to th…
View article: Efficacy of early use of remdesivir: a systematic review of subgroup analysis
Efficacy of early use of remdesivir: a systematic review of subgroup analysis Open
Introduction. A possible benefit has been suggested for early treatment of severe coronavirus disease 2019 (COVID-19) with remdesivir. The efficacy of this drug is controversial and could significantly influence the efficiency in healthcar…
View article: 4CPS-166 Association between immune-related effects and effectiveness of first-line pembrolizumab in advanced non-small-cell lung cancer
4CPS-166 Association between immune-related effects and effectiveness of first-line pembrolizumab in advanced non-small-cell lung cancer Open
Background and importance Pembrolizumab in monotherapy (in patients with PD-L1 expression ≥50%) or in combination with platinum-based chemotherapy (CT) (PDL-1 <50%) is the new standard therapy in first-line treatment of advanced or metasta…
View article: Response to the letter to the editor
Response to the letter to the editor Open
First of all, the authors are grateful for the comments [[1]Zou D, Niyazov A, Arondekar B, wu S. Letter to editor: cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. Breast. [In pre…
View article: Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews
Safety considerations during prescription of non-steroidal anti-inflammatory drugs (NSAIDs), through a review of systematic reviews Open
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs worldwide. This makes it necessary to carry out a comprehensive synthesis of the available evidence on the safe and adequate prescription of NSAIDs in pati…
View article: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain Open
View article: Remdesivir and mortality reduction in COVID-19 patients: a systematized subgroup analysis of clinical trials.
Remdesivir and mortality reduction in COVID-19 patients: a systematized subgroup analysis of clinical trials. Open
View article: Multiple-Organ Extracorporeal Support Therapies in Critically Ill Patients
Multiple-Organ Extracorporeal Support Therapies in Critically Ill Patients Open
The critically ill patient is capable of presenting a multiple organ dysfunction syndrome (MODS) caused by different diseases, which can be infectious (sepsis, septic shock) as well as non-infectious (pancreatitis, large surgeries, traumat…
View article: 2SPD-009 Analysis of olaparib and talazoparib as possible therapeutic alternatives in advanced breast cancer and a germline BRCA mutation
2SPD-009 Analysis of olaparib and talazoparib as possible therapeutic alternatives in advanced breast cancer and a germline BRCA mutation Open
Background To date, the main treatment in advanced breast cancer (ABC) with BRCA mutation is a non-specific chemotherapy of the physician's choice. Purpose To establish whether olaparib and talazoparib can be declared equivalent therapeuti…
View article: [Controversies about the mechanism of postcoital levonorgestrel: evidences according to the decrease of pregnancies].
[Controversies about the mechanism of postcoital levonorgestrel: evidences according to the decrease of pregnancies]. Open
View article: Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta. Open
View article: Píldora poscoital: un debate científico necesario
Píldora poscoital: un debate científico necesario Open
View article: New graphic AUC-based method to estimate overall survival benefit: pomalidomide reanalysis
New graphic AUC-based method to estimate overall survival benefit: pomalidomide reanalysis Open
This 2-month differential would have major clinical and pharmacoeconomic implications, on both cost-effectiveness studies and on the willingness of the healthcare systems to pay for this treatment.
View article: [Vedolizumab in Crohn Disease genesis-sefh drug evaluation report].
[Vedolizumab in Crohn Disease genesis-sefh drug evaluation report]. Open